Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Losing a Malpractice Case May Depend on Where You Live
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
The Role We Play in Addressing Racial Disparity in Dermatology
The Mainstream Patient: February 2